CN101528730A - 作为韩蛙皮素受体亚型-3调节剂的取代的咪唑 - Google Patents

作为韩蛙皮素受体亚型-3调节剂的取代的咪唑 Download PDF

Info

Publication number
CN101528730A
CN101528730A CNA2007800387313A CN200780038731A CN101528730A CN 101528730 A CN101528730 A CN 101528730A CN A2007800387313 A CNA2007800387313 A CN A2007800387313A CN 200780038731 A CN200780038731 A CN 200780038731A CN 101528730 A CN101528730 A CN 101528730A
Authority
CN
China
Prior art keywords
alkyl
unsubstituted
cycloalkyl
halogen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800387313A
Other languages
English (en)
Chinese (zh)
Inventor
D·陈
C·L·弗兰克林
P·R·古佐
L·S·林
M·M-C·罗
R·P·纳冈
I·K·塞巴特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN101528730A publication Critical patent/CN101528730A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2007800387313A 2006-10-20 2007-10-16 作为韩蛙皮素受体亚型-3调节剂的取代的咪唑 Pending CN101528730A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85319306P 2006-10-20 2006-10-20
US60/853,193 2006-10-20

Publications (1)

Publication Number Publication Date
CN101528730A true CN101528730A (zh) 2009-09-09

Family

ID=39325111

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800387313A Pending CN101528730A (zh) 2006-10-20 2007-10-16 作为韩蛙皮素受体亚型-3调节剂的取代的咪唑

Country Status (13)

Country Link
US (1) US8193228B2 (https=)
EP (1) EP2091937A2 (https=)
JP (1) JP5047299B2 (https=)
KR (1) KR20090064458A (https=)
CN (1) CN101528730A (https=)
AU (1) AU2007309570B2 (https=)
BR (1) BRPI0717976A2 (https=)
CA (1) CA2666310C (https=)
IL (1) IL198004A0 (https=)
MX (1) MX2009004112A (https=)
NO (1) NO20091957L (https=)
RU (1) RU2009118935A (https=)
WO (1) WO2008051406A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103497159A (zh) * 2013-09-18 2014-01-08 苏州岚云医药科技有限公司 1,2-二取代-5-磺酰基咪唑类化合物的制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
US8106070B2 (en) 2006-10-20 2012-01-31 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
WO2009123164A1 (ja) * 2008-04-02 2009-10-08 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013135674A1 (en) * 2012-03-12 2013-09-19 Syngenta Participations Ag Insecticidal 2-aryl-acetamide compounds
AU2016342027B2 (en) 2015-10-23 2021-05-13 Navitor Pharmaceuticals, Inc. Modulators of Sestrin-GATOR2 interaction and uses thereof
PL3615019T3 (pl) 2017-04-26 2026-01-19 Navitor Pharmaceuticals, Inc. Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie
EP3870158A4 (en) 2018-10-24 2022-08-10 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
US11723890B2 (en) 2019-11-01 2023-08-15 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962117A (en) * 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
JPH07243068A (ja) 1994-03-08 1995-09-19 Murata:Kk 金属表面の電解処理方法
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
AU730224B2 (en) 1996-12-23 2001-03-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
JPH11217348A (ja) 1997-10-15 1999-08-10 Otsuka Pharmaceut Co Ltd フルオレノン誘導体の製造法
EP1042299A1 (en) 1997-12-22 2000-10-11 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
AR024077A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
JP3842976B2 (ja) * 2000-03-17 2006-11-08 富士通株式会社 分布帰還型半導体レーザとその製造方法
EP1310494B1 (en) 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
WO2002098840A1 (en) 2001-06-04 2002-12-12 Eisai Co., Ltd. Carboxylic acid derivative and medicine comprising salt or ester of the same
BRPI0211844B8 (pt) 2001-08-10 2021-05-25 Nippon Chemiphar Co composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2003321455A (ja) 2002-02-28 2003-11-11 Nissan Chem Ind Ltd ｏ−置換ベンゾイル化合物及びこれを有効成分とする除草剤
DE10224844A1 (de) 2002-06-05 2004-01-08 Solvay Pharmaceuticals Gmbh Nicht-peptidische BRS-3-Agonisten
JPWO2004007464A1 (ja) 2002-07-10 2005-11-10 住友製薬株式会社 イミダゾール誘導体
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AU2003290120A1 (en) 2002-11-19 2004-06-15 Galderma Research & Development, S.N.C. Biaromatic compounds which activate PPAR-Gama type receptors, and use thereof in cosmetic or pharmaceutical compositions
PL376736A1 (pl) 2002-11-25 2006-01-09 Galderma Research & Development, S.N.C. Nowe związki diaromatyczne, które aktywują receptor typu PPAR<$Egamma> i ich zastosowanie w kompozycjach kosmetycznych lub farmaceutycznych
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
CA2514363A1 (en) 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
CA2548513A1 (en) * 2003-12-04 2005-07-07 Wyeth Biaryl sulfonamides and methods for using same
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
CA2551909C (en) * 2004-02-12 2011-10-11 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
GB0403578D0 (en) 2004-02-18 2004-03-24 Biofocus Discovery Ltd Compounds which interact with the G-protein coupled receptor family
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US8106070B2 (en) * 2006-10-20 2012-01-31 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103497159A (zh) * 2013-09-18 2014-01-08 苏州岚云医药科技有限公司 1,2-二取代-5-磺酰基咪唑类化合物的制备方法
CN103497159B (zh) * 2013-09-18 2015-08-12 苏州岚云医药科技有限公司 1,2-二取代-5-磺酰基咪唑类化合物的制备方法

Also Published As

Publication number Publication date
NO20091957L (no) 2009-07-17
AU2007309570A1 (en) 2008-05-02
CA2666310C (en) 2012-07-31
MX2009004112A (es) 2009-05-11
WO2008051406A3 (en) 2008-07-24
US20100022598A1 (en) 2010-01-28
CA2666310A1 (en) 2008-05-02
WO2008051406A2 (en) 2008-05-02
US8193228B2 (en) 2012-06-05
JP5047299B2 (ja) 2012-10-10
IL198004A0 (en) 2009-12-24
JP2010506919A (ja) 2010-03-04
KR20090064458A (ko) 2009-06-18
EP2091937A2 (en) 2009-08-26
AU2007309570B2 (en) 2012-07-12
RU2009118935A (ru) 2010-11-27
BRPI0717976A2 (pt) 2013-11-12

Similar Documents

Publication Publication Date Title
CN101528730A (zh) 作为韩蛙皮素受体亚型-3调节剂的取代的咪唑
JP5319550B2 (ja) 置換スピロクロマノン誘導体
TWI393709B (zh) 可作為抗糖尿病劑之新穎環苯并咪唑衍生物
JP5271917B2 (ja) スピロクロマノン誘導体
JP5076159B2 (ja) アセチルコエンザイムａカルボキシラーゼ（ａｃｃ）阻害薬としてのスピロクロマノン誘導体
AU2007238771A1 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
EP2102201B1 (en) Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
US8183275B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2007254323A1 (en) Pro-drugs of tertiary alcohols
US8318767B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2006320797A1 (en) Heterocycle-substituted 3-alkyl azetidine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090909